species PhS+ C. Subsequently, the regioselectively electrophilic attack of PhS+ C on imidazole ring to form imidazolium intermediate
D, which can undergo proton elimination to afford the desired product 3aa, with the concomitant formation of copper catalyst. At the
same time, the PhSH could reproduce diphenyl disulfide by O2 to complete the catalytic cycle.
Scheme 3. Proposed reaction mechanism.
In summary, we have developed a simple and efficient method for synthesis of sulfenylimidazo[1,2-a]pyridines by copper-catalyzed
one-pot three-component system with arylboronic acids and elemental sulfur. Further more, The method has a broad substrate scope,
with a variety of substituent groups on aryl boronicacids as well as 2-arylimidazo[1,2-a]pyridines. In addition, efforts to extend the
applications of the transformation in organic synthesis as well as screen for biological activity of these types of compounds are now in
progress in our laboratory (General experimental procedures and spectral data of product are provided in supporting information).
Acknowledgments
This work was supported by the National Natural Science Foundation of China (Nos. 21072054, 21572051, 21602057), the
Ministry of Education of China (No. 213027A), and the Scientific Research Fund of Hunan Provincial Education Department
(No. 15A109).
References
[1] (a) A.R. Ali, E.R. El-Bendary, M.A. Ghaly, I.A. Shehata, Eur. J. Med. Chem. 75 (2014) 492-500;
(b) Y. Matsuya, Y. Kobayashi, S. Uchida, et al., Bioorg. Med. Chem. Lett. 23 (2013) 4907-4910;
(c) R. Budriesi, P. Ioan, A. Leoni, et al., J. Med. Chem. 54 (2011) 3885-3894;
(d) K.F. Byth, C. G., C.L. Forder, S.E. Oakes, A.P. Thomas, Mol. Cancer Ther. 5 (2006) 655-664;
(e) K. Mizushige, T. Ueda, K. Yukiiri, H. Suzuki, Cardiova. Drug Rev. 20 (2002) 163-174;
(f) K.C. Rupert, J.R. Henry, J.H. Dodd, et al., Bioorg. Med. Chem. Lett. 13 (2003) 347-350;
(g) Y. Abe, H. Kayakiri, S. Satoh, et al., J. Med. Chem. 41(1998) 4587-4598.
[2] (a) T. Okubo, R. Yoshikawa, S. Chaki, S. Okuyamac, A. Nakazatoa, Bioorg. Med. Chem. Lett. 12 (2004) 423-438;
(b) A. Berson, V. Descatoire, A. Sutton, et al., J. Pharmacol. Exp. Ther. 299 (2001) 793-800;
(c) P.G. George, G. Rossey, M. Sevrin, et al., Monogr. Ser. 8 (1993) 49-65.
[3] (a) B. Du, A. Shan, Y. Zhang, et al., Am. J. Med. Sci. 347 (2014) 178-182;
(b) S.M. Hanson, E.V. Morlock, K.A. Satyshur, C. Czajkowski, J. Med. Chem. 51 (2008) 7243-7252.
[4] H. Depoortere, P. George, US 5064836, 1991.
[5] D.J. Sanger, Behav. Pharmacol. 6 (1995) 116-126.
[6] (a) D. Belohlavek, P. Malfertheiner, Scand J Gastroenterol Suppl 54 (1979) 44-44;
(b) L. Almirante, L. Polo, A. Mugnaini, et al., J. Med. Chem. 8 (1965) 305-312.
[7] L.A. Sorbera, J. Castaner, P.A. Leeson, Drugs Future 27 (2002) 935-941.
[8] (a) T. Ueda, K. Mizusgige, K. Yukiiri, T. Takahashi, Cerebrovasc. Dis. 16 (2003) 396-401;
(b) K. Mizushige, T. Ueda, K. Yukiiri, H. Suzuki, Cardiovasc. Drug Rev. 20 (2002) 163-174;
(c) Y. Uemura, S. Tanaka, S. Ida, T.J. Yuzuriha, J. Pharm. Pharmacol. 45 (1993) 1077-1081.
[9] (a) H. Liu, X. Jiang, Chem. Asian J. 8 (2013) 2546-2563;
(b) A. Gangjee, Y. Zeng, T. Talreja, et al., J. Med. Chem. 50 (2007) 3046-3053;
(c) G. De Martino, M.C. Edler, G. La Regina, et al., J. Med. Chem. 49 (2006) 947-954;
(d) A.M. Faucher, P.W. White, C. Brochu, et al., J. Med. Chem. 47 (2004) 18-21;
(e) G. Liu, J.R. Huth, E.T. Olejniczak, et al., J. Med. Chem. 44 (2001) 1202-1210;
(f) C.M. Rayner, Contemp. Org. Synth. 2 (1995) 409-440.
[10] (a) C. Ravi, A. Joshi, S. Adimurthy, Eur. J. Org. Chem. 25 (2017) 3646-3651;
(b) J. Rafique, S. Saba, A.R. Rosário, A.L. Braga, Chem. Eur. J. 22 (2016) 1-10;
(c) Z. Gao, X. Zhu, R. Zhang, RSC Adv. 4 (2014) 19891-19895;
(d) D.C. Mohan, S.N. Rao, C. Ravi, S. Adimurthy, Asian J. Org. Chem. 3 (2014) 609-613;
(e) W. Ge, X. Zhu, Y. Wei, Eur. J. Org. Chem. 2013 (2013) 6015-6020;
(f) Z. Li, J. Hong, X. Zhou, Tetrahedron 67 (2011) 3690-3697.
[11] (a) C. Ravi, D.C. Mohan, S. Adimurthy, Org. Biomol. Chem. 14 (2016) 2282-2290;
(b) Z. Zheng, D. Qi, L. Shi, Catalysis Communications 66 (2015) 83-86;